Business Description
Zevra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4884452065
Description
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.49 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.86 | |||||
| Debt-to-EBITDA | -0.77 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2 | |||||
| Beneish M-Score | 38.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -38.5 | |||||
| 3-Year EBITDA Growth Rate | 3.4 | |||||
| 3-Year EPS without NRI Growth Rate | 23.7 | |||||
| 3-Year FCF Growth Rate | -24.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 102.71 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.24 | |||||
| 9-Day RSI | 45.31 | |||||
| 14-Day RSI | 51.07 | |||||
| 6-1 Month Momentum % | 93.4 | |||||
| 12-1 Month Momentum % | 72.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.88 | |||||
| Quick Ratio | 2.88 | |||||
| Cash Ratio | 2.59 | |||||
| Days Sales Outstanding | 152.29 | |||||
| Days Payable | 514.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -109.2 | |||||
| Shareholder Yield % | -20.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.13 | |||||
| Operating Margin % | -354.22 | |||||
| Net Margin % | -366.14 | |||||
| FCF Margin % | -284.28 | |||||
| ROE % | -159.89 | |||||
| ROA % | -56.14 | |||||
| ROIC % | -93.41 | |||||
| ROC (Joel Greenblatt) % | -5464.64 | |||||
| ROCE % | -68.84 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.86 | |||||
| PB Ratio | 6.79 | |||||
| EV-to-EBIT | -5.32 | |||||
| EV-to-Forward-EBIT | -2.97 | |||||
| EV-to-EBITDA | -5.7 | |||||
| EV-to-Forward-EBITDA | -21.84 | |||||
| EV-to-Revenue | 18.2 | |||||
| EV-to-Forward-Revenue | 5.15 | |||||
| EV-to-FCF | -6.4 | |||||
| Earnings Yield (Greenblatt) % | -18.8 | |||||
| FCF Yield % | -14.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zevra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 22.461 | ||
| EPS (TTM) (€) | -1.931 | ||
| Beta | 0.47 | ||
| Volatility % | 51.88 | ||
| 14-Day RSI | 51.07 | ||
| 14-Day ATR (€) | 0.258004 | ||
| 20-Day SMA (€) | 8.5175 | ||
| 12-1 Month Momentum % | 72.27 | ||
| 52-Week Range (€) | 3.76 - 9.15 | ||
| Shares Outstanding (Mil) | 53.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zevra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zevra Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zevra Therapeutics Inc Frequently Asked Questions
What is Zevra Therapeutics Inc(STU:1GDA)'s stock price today?
The current price of STU:1GDA is €8.40. The 52 week high of STU:1GDA is €9.15 and 52 week low is €3.76.
When is next earnings date of Zevra Therapeutics Inc(STU:1GDA)?
The next earnings date of Zevra Therapeutics Inc(STU:1GDA) is 2025-03-28 Est..
Does Zevra Therapeutics Inc(STU:1GDA) pay dividends? If so, how much?
Zevra Therapeutics Inc(STU:1GDA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers